Does thrombolytic therapy facilitate or foil primary PCI?

New England Journal of Medicine

Volumn 358, Issue 21, 2008, Pages 2277-2279

  Leopold, Jane A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; RETEPLASE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

EID: 44249109992     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0801533     Document Type: Editorial

References (14)

1. TJ Kiernan HH Ting BJ Gersh Facilitated percutaneous coronary intervention: current concepts, promises, and pitfalls. Eur Heart J 28 2007 1545 1553
2. RL McNamara Y Wang J Herrin Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 47 2006 2180 2186
3. BK Nallamothu ER Bates Y Wang EH Bradley HM Krumholz Driving times and distances to hospitals with percutaneous coronary intervention in the United States: implications for prehospital triage of patients with ST-elevation myocardial infarction. Circulation 113 2006 1189 1195
4. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006;367:579-88. [Erratum, Lancet 2006;367:1656.]
5. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 2006 569 578
6. MC Sinno S Khanal MH Al-Mallah M Arida WD Weaver The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. Am Heart J 153 2007 579 586
7. SG Ellis M Tendera MA de Belder Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 2008 2205 2217
8. BJ Gersh GW Stone HD White DR Holmes Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 293 2005 979 986
9. GW Stone D Cox E Garcia Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 2001 636 641
10. GW Stone MA Peterson AJ Lansky G Dangas R Mehran MB Leon Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol 39 2002 591 597
11. C Basso G Thiene The pathophysiology of myocardial reperfusion: a pathologist's perspective. Heart 92 2006 1559 1562
12. SA Coulter CP Cannon KA Ault High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14. Circulation 101 2000 2690 2695
13. P Harrison I Mackie A Mathur Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 16 2005 557 562
14. M Piorkowski J Priess U Weikert Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction. Thromb Haemost 94 2005 422 426